caa a22 4500 46573958X CHVBK 20180323111805.0 cr unu---uuuuu 170327e19900201xx s 000 0 eng 10.1007/BF02244401 doi (NATIONALLICENCE)springer-10.1007/BF02244401 Yawning induced by apomorphine, physostigmine or pilocarpine is potentiated by dihydropyridine calcium channel blockers [Elektronische Daten] [Anne Bourson, Paul Moser] Previous studies have shown that dihydropyridine (DHP) calcium channel blockers can potentiate yawning induced by apomorphine in rats. The present study was undertaken to examine whether or not this interaction was seen with other compounds that induce yawning or if it represented a specific interaction with dopaminergic mechanisms. Yawning induced by apomorphine (40 µg/kg SC), physostigmine (50 µg/kg SC) or pilocarpine (1 mg/kg SC) was dose-dependently potentiated by the DHP calcium channel blocker nifedipine (1.25-10 mg/kg IP). Nimodipine (1.25-5 mg/kg IP) and nitrendipine (1.25-5 mg/kg IP) also significantly increased the yawning response. The DHP calcium channel blockers alone induced only a low incidence of yawning. The effects of nifedipine on physostigmine-induced yawning were reversed by the DHP calcium channel activator BAY K 8644 which also inhibited yawning induced by physostigmine (100 µg/kg SC) and pilocarpine (2 mg/kg SC). In contrast to the DHP compounds, diltiazem (2.5-10 mg/kg IP) and verapamil (2.5-10 mg/kg IP) failed to potentiate yawning. Sulpiride (10 mg/kg SC) antagonised the nifedipine potentiation of apomorphine-induced yawning but not that of physostigmine-induced yawning; atropine (2.5 mg/kg SC) antagonised both effects. These results support the hypothesis that this effect of dihydropyridine compounds is not dependent on, nor mediated through, dopaminergic mechanisms. Springer-Verlag, 1990 Yawning nationallicence Nifedipine nationallicence BAY K 8644 nationallicence Apomorphine nationallicence Physostigmine nationallicence Pilocarpine nationallicence Bourson Anne Merrell Dow Research Institute, 16, rue d'Ankara, F-67084, Strasbourg Cédex, France aut Moser Paul Merrell Dow Research Institute, 16, rue d'Ankara, F-67084, Strasbourg Cédex, France aut Psychopharmacology Springer-Verlag 100/2(1990-02-01), 168-172 0033-3158 100:2<168 1990 100 213 https://doi.org/10.1007/BF02244401 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02244401 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Bourson Anne Merrell Dow Research Institute, 16, rue d'Ankara, F-67084, Strasbourg Cédex, France aut NATIONALLICENCE 700 1- Moser Paul Merrell Dow Research Institute, 16, rue d'Ankara, F-67084, Strasbourg Cédex, France aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 100/2(1990-02-01), 168-172 0033-3158 100:2<168 1990 100 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer